The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

Sen. Ron Wyden and other Democrats claim Pfizer used a "colossal" scheme to avoid paying billions in U.S. taxes.

Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...